
GSK appoints Hans Wijers to its Board as a non-executive director
pharmafile | January 28, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | GSK, hans Wijers
GSK has confirmed the appointment of Hans Wijers to its Board as a non-executive director with effect from April.
The appointment is subject to shareholder approval at the firm’s annual general meeting. Wijers is currently a non-executive director and chairman designate of Heineken, one of the world’s largest brewers.
He is also currently deputy chairman and non-executive director of Royal Dutch Shell. Previously, Wijers was chief executive and chairman at AkzoNobel, a world-leading paints and coating company and a major producer of speciality chemicals, a position he held for 10 years.
Prior to joining Akzo Nobel, Wijers held positions as minister for economic affairs for the government of the Netherlands as well as in the private sector with the Boston Consulting Group.
Commenting on the appointment, Sir Christopher Gent, chairman of GSK, said:
“I am delighted to welcome Hans to the Board. His broad business experience, including as chief executive of AkzoNobel, together with his economic and political knowledge will enable him to make a significant contribution to the future success of GSK.”
Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …





